BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aquino A, Alexandrino GL, Guest PC, Augusto F, Gomes AF, Murgu M, Steiner J, Martins-de-Souza D. Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients. Front Psychiatry 2018;9:209. [PMID: 29887809 DOI: 10.3389/fpsyt.2018.00209] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Couttas TA, Jieu B, Rohleder C, Leweke FM. Current State of Fluid Lipid Biomarkers for Personalized Diagnostics and Therapeutics in Schizophrenia Spectrum Disorders and Related Psychoses: A Narrative Review. Front Psychiatry 2022;13:885904. [PMID: 35711577 DOI: 10.3389/fpsyt.2022.885904] [Reference Citation Analysis]
2 Karahalil B, Elkama A, Ak M, Nemutlu E. Metabolomics mapping changed after olanzapine therapy in drug-naive schizophrenia patients—the significant impact of gene polymorphisms. Toxicology Research 2022. [DOI: 10.1093/toxres/tfac034] [Reference Citation Analysis]
3 Smith BJ, Silva-Costa LC, Martins-de-Souza D. Human disease biomarker panels through systems biology. Biophys Rev 2021;13:1179-90. [PMID: 35059036 DOI: 10.1007/s12551-021-00849-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Zhou CH, Xue SS, Xue F, Liu L, Liu JC, Ma QR, Qin JH, Tan QR, Wang HN, Peng ZW. The impact of quetiapine on the brain lipidome in a cuprizone-induced mouse model of schizophrenia. Biomed Pharmacother 2020;131:110707. [PMID: 32905942 DOI: 10.1016/j.biopha.2020.110707] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
5 Horska K, Kotolova H, Karpisek M, Babinska Z, Hammer T, Prochazka J, Stark T, Micale V, Ruda-Kucerova J. Metabolic profile of methylazoxymethanol model of schizophrenia in rats and effects of three antipsychotics in long-acting formulation. Toxicol Appl Pharmacol 2020;406:115214. [PMID: 32866524 DOI: 10.1016/j.taap.2020.115214] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
6 Seabra G, de Almeida V, Reis-de-Oliveira G, Crunfli F, Antunes ASLM, Martins-de-Souza D. Ubiquitin-proteasome system, lipid metabolism and DNA damage repair are triggered by antipsychotic medication in human oligodendrocytes: implications in schizophrenia. Sci Rep 2020;10:12655. [PMID: 32724114 DOI: 10.1038/s41598-020-69543-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
7 Garcia-rosa S, Carvalho BS, Guest PC, Steiner J, Martins-de-souza D. Blood plasma proteomic modulation induced by olanzapine and risperidone in schizophrenia patients. Journal of Proteomics 2020;224:103813. [DOI: 10.1016/j.jprot.2020.103813] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
8 de Almeida V, Alexandrino GL, Aquino A, Gomes AF, Murgu M, Dobrowolny H, Guest PC, Steiner J, Martins-de-Souza D. Changes in the blood plasma lipidome associated with effective or poor response to atypical antipsychotic treatments in schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry 2020;101:109945. [PMID: 32304808 DOI: 10.1016/j.pnpbp.2020.109945] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
9 de Almeida V, Alexandrino GL, Aquino A, Gomes AF, Murgu M, Guest PC, Steiner J, Martins-de-souza D. Changes in the blood plasma lipidome associated with response to atypical antipsychotic treatments in schizophrenia.. [DOI: 10.1101/2020.03.25.008474] [Reference Citation Analysis]
10 Tse BCY, Byrne SN. Lipids in ultraviolet radiation-induced immune modulation. Photochem Photobiol Sci 2020;19:870-8. [DOI: 10.1039/d0pp00146e] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
11 Sinclair K, Dudley E. Metabolomics and Biomarker Discovery. Adv Exp Med Biol 2019;1140:613-33. [PMID: 31347075 DOI: 10.1007/978-3-030-15950-4_37] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
12 Martins-de-Souza D, Guest PC, Steiner J. A proteomic signature associated to atypical antipsychotic response in schizophrenia patients: a pilot study. Eur Arch Psychiatry Clin Neurosci 2020;270:127-34. [PMID: 30937516 DOI: 10.1007/s00406-019-01002-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Gotoh L, Yamada M, Hattori K, Sasayama D, Noda T, Yoshida S, Kunugi H, Yamada M. Levels of lysophosphatidic acid in cerebrospinal fluid and plasma of patients with schizophrenia. Psychiatry Res 2019;273:331-5. [PMID: 30682553 DOI: 10.1016/j.psychres.2019.01.052] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
14 Leppik L, Parksepp M, Janno S, Koido K, Haring L, Vasar E, Zilmer M. Profiling of lipidomics before and after antipsychotic treatment in first-episode psychosis. Eur Arch Psychiatry Clin Neurosci 2020;270:59-70. [PMID: 30604052 DOI: 10.1007/s00406-018-0971-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
15 Burghardt KJ, Ward KM, Sanders EJ, Howlett BH, Seyoum B, Yi Z. Atypical Antipsychotics and the Human Skeletal Muscle Lipidome. Metabolites 2018;8:E64. [PMID: 30322152 DOI: 10.3390/metabo8040064] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]